Program
Alendronate
Also written as “alendronate”, “Comparator: alendronate” and “Liposomal Alendronate”.
Its studies are mostly in Osteoporosis, Postmenopausal · Osteoporosis · Osteitis Deformans · Coronary Stenosis · Back Pain, led by 8 companies.
Drug pageAlendronate: every studyMany companies study it; this page follows only the 17 they lead. All 91 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organonits history only | 90 open or running | phase 4since Aug 5, 2008 | Sep 21, 2004 | none ahead |
| Viatris | 20 open or running | phase 1since Sep 21, 2009 | Sep 21, 2009 | none ahead |
| BIOrestits history only | 10 open or running | phase 2since Aug 20, 2008 | Aug 20, 2008 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 10 open or running | phase 1since May 27, 2010 | May 27, 2010 | none ahead |
| Evangelisches Krankenhaus Lutherhaus gGmbHits history only | 10 open or running | phase 3since Jan 11, 2012 | Jan 11, 2012 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 4since May 18, 2006 | May 18, 2006 | none ahead |
| Radius Healthits history only | 10 open or running | phase 3since Jul 31, 2012 | Jul 31, 2012 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 1since Jan 30, 2009 | Jan 30, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Viatris only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 21, 2009First studies: 2 phase 1 studies in HealthyFirst studyNCT01012934, NCT00983996
TargetBeta
“Farnesyl diphosphate synthase inhibitor”ChEMBL 37, by rule
Studies
All 2 Viatris leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01012934Healthy · United States | 1 | Completed | Aug 2002 | 110 |
| NCT00983996Healthy · United States | 1 | Completed | Jul 2002 | 112 |
How it is read
Names in the registry
- “Alendronate”, 7 entries
- “alendronate”, 2 entries
- “Comparator: alendronate”, 2 entries
- “Liposomal Alendronate”, 2 entries
- “Alendronate Sodium Tablets, 70 mg”, 2 entries
Codes read as this program: MK0217.
Conditions, from the studies’ own filings
- Osteoporosis, Postmenopausal, 7 studies
- Osteoporosis, 6 studies
- Osteitis Deformans, 1 study
- Coronary Stenosis, 1 study
- Back Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.